---
title: "Psilocybin (COMP360) in Treatment-resistant depression: References"
description: "Reference list for the formulary evidence report on Psilocybin (COMP360) in Treatment-resistant depression. 261 cited documents."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: References

<a id="references"></a>

## 5 References

1. [Aaronson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28359201/)
2. [Aaronson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741440/)
3. [Abilify prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf)
4. [Akil et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729118/)
5. [American Psychiatric Association (2010)](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)
6. [Amos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29474009/)
7. [Anand et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224232/)
8. [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/)
9. [Becker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9299061/)
10. [Benson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31735488/)
11. [Bergfeld et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27049915/)
12. [Bergfeld et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29665520/)
13. [Blumberger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29726344/)
14. [Borgogna et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449434/)
15. [Bosco-Lévy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767421/)
16. [Brenner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8047832/)
17. [Brenner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12996023/)
18. [Brown et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28353056/)
19. [Brown et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6591751/)
20. [Butler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481484/)
21. [Cai et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31540559/)
22. [Cepeda et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5873404/)
23. [Cepeda et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055726/)
24. [Chaikali et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42127355/)
25. [Chamberlain et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6124647/)
26. [Cheng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10993159/)
27. [Chisamore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11948223/)
28. [Cleare et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40113355/)
29. [Clemens et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/43010363/)
30. [ClinicalTrials.gov NCT03775200](https://clinicaltrials.gov/study/NCT03775200)
31. [ClinicalTrials.gov NCT03775200 results](https://clinicaltrials.gov/study/NCT03775200?tab=results)
32. [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)
33. [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)
34. [ClinicalTrials.gov NCT04959253](https://clinicaltrials.gov/study/NCT04959253)
35. [ClinicalTrials.gov NCT05624268](https://clinicaltrials.gov/study/NCT05624268)
36. [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)
37. [ClinicalTrials.gov NCT05733546](https://clinicaltrials.gov/study/NCT05733546)
38. [ClinicalTrials.gov NCT07226232](https://clinicaltrials.gov/study/NCT07226232)
39. [ClinicalTrials.gov NCT07570654](https://clinicaltrials.gov/study/NCT07570654)
40. [CMS 2027 Adult Core Set](https://www.medicaid.gov/medicaid/quality-of-care/downloads/2027-adult-core-set.pdf)
41. [CMS vagus nerve stimulation national coverage determination (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=230)
42. [Cole et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34711062/)
43. [COMPASS Pathways (2018)](https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx)
44. [COMPASS Pathways COMP001 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/Prot_000.pdf)
45. [COMPASS Pathways COMP001 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/00/NCT03775200/SAP_001.pdf)
46. [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)
47. [COMPASS Pathways COMP006 26-week presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm)
48. [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)
49. [COMPASS Pathways executive order release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Commends-White-House-Executive-Order-to-Accelerate-Research-and-Access-for-Psychedelic-Treatments/default.aspx)
50. [COMPASS Pathways first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/q12025pressrelease.htm)
51. [COMPASS Pathways first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/q12026pressrelease.htm)
52. [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)
53. [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)
54. [COMPASS Pathways Form 8-K COMP005 topline (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm)
55. [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)
56. [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)
57. [COMPASS Pathways fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)
58. [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)
59. [COMPASS Pathways NEJM publication release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-announces-publication-of-phase-2b-study-of-COMP360-psilocybin-therapy-for-treatment-resistant-depression-in-The-New-England-Journal-of-Medicine/default.aspx)
60. [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)
61. [COMPASS Pathways phase 3 design release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-Announces-Phase-3-Pivotal-Program-Design-for-COMP360-in-Treatment-Resistant-Depression-at-Capital-Markets-Day/default.aspx)
62. [COMPASS Pathways PIVOT release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx)
63. [COMPASS Pathways provider training grant release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-U-S--Grant-Program-Recipients-for-the-Development-of-Post-Approval-COMP360-Provider-Training/default.aspx)
64. [COMPASS Pathways Psych Congress release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Debut-U-S--HCP-Education-Campaign-and-Present-New-HEOR-Data-at-Psych-Congress-2026/default.aspx)
65. [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx)
66. [COMPASS Pathways second quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024033854/q22024pressrelease.htm)
67. [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)
68. [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)
69. [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)
70. [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)
71. [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)
72. [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)
73. [Conway et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27784055/)
74. [Conway et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39706521/)
75. [Conway et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799215/)
76. [Conway et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42642808/)
77. [Daly et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551577/)
78. [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/)
79. [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)
80. [Dodd et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35811423/)
81. [Dougherty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226623/)
82. [Dougherty et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42460632/)
83. [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)
84. [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)
85. [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)
86. [eCQI Resource Center CMS159 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0159v14)
87. [eCQI Resource Center CMS2 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0002v15)
88. [Ellis et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39343309/)
89. [Ellis et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40499827/)
90. [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)
91. [Fabbri et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8505242/)
92. [Fava (2003)](https://pubmed.ncbi.nlm.nih.gov/12706951/)
93. [FDA (2018)](https://www.fda.gov/media/113988/download)
94. [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)
95. [FDA SAINT Neuromodulation System clearance (2022)](https://www.accessdata.fda.gov/cdrh_docs/pdf22/K220177.pdf)
96. [Fekadu et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19007996/)
97. [Fekadu et al. (2009b)](https://pubmed.ncbi.nlm.nih.gov/19192471/)
98. [Fekadu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5896127/)
99. [Fife et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6076365/)
100. [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)
101. [Gaynes et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31638723/)
102. [George et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20439832/)
103. [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)
104. [Goodwin et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36740140/)
105. [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)
106. [Goodwin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37434509/)
107. [Goodwin et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39706482/)
108. [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)
109. [Goodwin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41881122/)
110. [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/)
111. [Gukasyan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37291890/)
112. [Guo et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26315978/)
113. [Haikazian et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37844352/)
114. [Halman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/)
115. [Hamilton (1960)](https://pmc.ncbi.nlm.nih.gov/articles/PMC495331/)
116. [Hasin et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875313/)
117. [Heerlein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33545659/)
118. [Heijnen et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20814336/)
119. [Hengartner and Plöderl (2022)](https://pubmed.ncbi.nlm.nih.gov/33593736/)
120. [Henssler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8851370/)
121. [Hieronymus et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311713/)
122. [Højlund et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41205366/)
123. [Holze et al. (2023)](https://doi.org/10.1002/cpt.2821)
124. [Hovmand et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10350724/)
125. [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)
126. [Huneke et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40072447/)
127. [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-therapy-for-treatment-resistant-depression/)
128. [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)
129. [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)
130. [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/)
131. [Ijaz et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6494651/)
132. [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)
133. [ISRCTN ISRCTN17905443 basic results (2024)](https://www.isrctn.com/editorial/retrieveFile/65a8139b-10a3-4341-b7e1-d15edeb0ab8e/45481)
134. [Ivanova et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20825269/)
135. [Iveson et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13245096/)
136. [Jaffe et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6686569/)
137. [Jamieson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10169482/)
138. [Jelovac et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799066/)
139. [Johnston et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30195173/)
140. [Jungwirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453954/)
141. [Kaster et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722479/)
142. [Kern et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454258/)
143. [Keshavan (2026)](https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/)
144. [Kessler et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6207929/)
145. [Kim and Na (2016)](https://pubmed.ncbi.nlm.nih.gov/27046518/)
146. [Kirlić et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741434/)
147. [Kirlić et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41362124/)
148. [Kratter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805067/)
149. [Kubitz et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799999/)
150. [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)
151. [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)
152. [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)
153. [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)
154. [Li et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6771113/)
155. [Lithobid prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018027s069lbl.pdf)
156. [Lorentzen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31977066/)
157. [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)
158. [Luoma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12304229/)
159. [Madras (2022)](https://www.nejm.org/doi/full/10.1056/NEJMe2210975)
160. [Madsen et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6785028/)
161. [Manevski et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835393/)
162. [Mann (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9873942/)
163. [Markopoulou et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8076168/)
164. [Marseille et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10731307/)
165. [Marwood et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39427449/)
166. [McAllister-Williams et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32217227/)
167. [McAllister-Williams et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008595/)
168. [McCrone et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755218/)
169. [McGrath et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946177/)
170. [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)
171. [Menon et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39627679/)
172. [Mertens et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000742/)
173. [Meshkat et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12030428/)
174. [Mohamed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817471/)
175. [Moncrieff et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340015/)
176. [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)
177. [Mrazek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24789696/)
178. [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)
179. [Mutz et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435996/)
180. [Nayak et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34348413/)
181. [Nayak et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37167563/)
182. [NCQA Antidepressant Medication Management](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/antidepressant-medication-management-amm/)
183. [NCQA Depression Remission or Response](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-remission-or-response-for-adolescents-and-adults-drr-e/)
184. [NCQA Depression Screening and Follow-Up](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-screening-and-follow-up-for-adolescents-and-adults-dsf-e/)
185. [NCQA HEDIS measure retirement plan (2023)](https://www.ncqa.org/blog/retiring-and-replacing-hedis-measures-2024-2026/)
186. [NCQA HEDIS MY 2025 changes (2024)](https://www.ncqa.org/blog/hedis-my-2025-whats-new-whats-changed-whats-retired/)
187. [Nelson et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25069082/)
188. [NICE (2015)](https://www.nice.org.uk/guidance/htg396/chapter/1-Recommendations)
189. [NICE (2020)](https://www.nice.org.uk/guidance/htg551/chapter/1-Recommendations)
190. [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)
191. [Nierenberg et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946176/)
192. [Nuñez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328668/)
193. [Nygren et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381860/)
194. [O'Reardon et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17573044/)
195. [Ochs-Ross et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31734084/)
196. [Oregon Health Authority](https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx)
197. [Orsini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41984443/)
198. [Østergaard and Hieronymus (2023)](https://www.nejm.org/doi/full/10.1056/NEJMc2215459)
199. [Papakostas et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12891091/)
200. [Perez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37557019/)
201. [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/)
202. [Pilon et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30734581/)
203. [Pilon et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6786597/)
204. [Pilon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8016289/)
205. [Popova et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31109201/)
206. [Psych Congress Elevate COMP005 26-week abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378888)
207. [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)
208. [Qaseem et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36689752/)
209. [Qaseem et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41802255/)
210. [Rathod et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34965398/)
211. [Reif et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37792613/)
212. [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/)
213. [Reutfors et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31774374/)
214. [Rexulti prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf)
215. [Rizvi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086317/)
216. [Rosenblat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720483/)
217. [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/)
218. [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)
219. [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)
220. [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)
221. [Ruhé et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21435727/)
222. [Runia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34890601/)
223. [Rush et al. (2006a)](https://pubmed.ncbi.nlm.nih.gov/16554525/)
224. [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)
225. [Rush et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39701918/)
226. [Sackeim (2001)](https://pubmed.ncbi.nlm.nih.gov/11480879/)
227. [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm)
228. [Sarparast et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/)
229. [Semkovska and McLoughlin (2010)](https://pubmed.ncbi.nlm.nih.gov/20673880/)
230. [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)
231. [Sforzini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9095475/)
232. [Silva-Carvalho et al. (2026)](https://revistas.rcaap.pt/revsalus/article/view/46635)
233. [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41906234/)
234. [Spielmans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3595214/)
235. [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)
236. [Strawbridge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244173/)
237. [Syed et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41587629/)
238. [Symbyax prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021520s056lbl.pdf)
239. [Szukis et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33879005/)
240. [Tai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/)
241. [Thase and Rush (1997)](https://pubmed.ncbi.nlm.nih.gov/9402916/)
242. [Thomann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11089204/)
243. [Thomas et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3839394/)
244. [Trivedi et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16554526/)
245. [Tsai et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40197402/)
246. [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)
247. [UK ECT Review Group (2003)](https://pubmed.ncbi.nlm.nih.gov/12642045/)
248. [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)
249. [van Bronswijk et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30139408/)
250. [Vraylar prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204370s014s015s016s017lbl.pdf)
251. [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)
252. [Wiles et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219570/)
253. [Wiles et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26777773/)
254. [Williams et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41848744/)
255. [Wolff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42903188/)
256. [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf)
257. [Zaki et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10267177/)
258. [Zhdanava et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391320/)
259. [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/)
260. [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/)
261. [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
